

1. NAME OF THE MEDICINAL PRODUCT

PRUCAWIN 2 film-coated tablets.

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each film coated tablet contains:

Prucalopride Succinate

Eq.to, Prucalopride 2 mg

For list of Excipients refer to 6.1

3. PHARMACEUTICAL FORM

Film-coated tablet (tablet).

A brown colored, round shaped, biconvex, film coated tablet, plain on both side.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

PRUCAWIN is indicated for symptomatic treatment of chronic constipation in adults in whom laxatives fail to provide adequate relief.

4.2 Posology and method of administration

Posology

Adults: 2 mg once daily with or without food, at any time of the day.

Due to the specific mode of action of prucalopride (stimulation of propulsive motility), exceeding the daily dose of 2 mg is not expected to increase efficacy.

If the intake of once daily prucalopride is not effective after 4 weeks of treatment, the patient should be re-examined and the benefit of continuing treatment reconsidered.

The efficacy of prucalopride has been established in double-blind, placebo-controlled studies for up to 3 months. Efficacy beyond three months has not been demonstrated in placebo-controlled studies (see Section 5.1). In case of prolonged treatment, the benefit should be reassessed at regular intervals.

Special populations

Older people (>65 years): Start with 1 mg once daily (see section 5.2); if needed the dose can be increased to 2 mg once daily.

Patients with renal impairment: The dose for patients with severe renal impairment (GFR <30 ml/min/1.73 m²) is 1 mg once daily (see sections 4.3 and 5.2). No dose adjustment is required for patients with mild to moderate renal impairment.

Patients with hepatic impairment: Patients with severe hepatic impairment (Child-Pugh class C) start with 1 mg once daily which may be increased to 2 mg if required to improve efficacy

and if the 1 mg dose is well tolerated (see sections 4.4 and 5.2). No dose adjustment is required for patients with mild to moderate hepatic impairment.

2

Paediatric population: PRUCAWIN should not be used in children and adolescents younger than 18 years (see section 5.1).

Method of administration

Oral use

4.3 Contraindications

- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
- Renal impairment requiring dialysis.
- Intestinal perforation or obstruction due to structural or functional disorder of the gut wall, obstructive ileus, severe inflammatory conditions of the intestinal tract, such as Crohn's disease, and ulcerative colitis and toxic megacolon/megarectum.

4.4 Special warnings and precautions for use

Renal excretion is the main route of elimination of prucalopride (see section 5.2). A dose of 1 mg is recommended in subjects with severe renal impairment (see section 4.2).

Caution should be exercised when prescribing PRUCAWIN to patients with severe hepatic impairment (Child-Pugh class C) due to limited data in patients with severe hepatic impairment (see section 4.2).

There is limited information on the safety and efficacy of PRUCAWIN for use in patients with severe and clinically unstable concomitant disease (e.g. cardiovascular or lung disease, neurological or psychiatric disorders, cancer or AIDS and other endocrine disorders). Caution should be exercised when prescribing PRUCAWIN to patients with these conditions especially when used in patients with a history of arrhythmias or ischaemic cardiovascular disease.

In case of severe diarrhoea, the efficacy of oral contraceptives may be reduced and the use of an additional contraceptive method is recommended to prevent possible failure of oral contraception (see the prescribing information of the oral contraceptive).

The tablets contain lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.

4.5 Interaction with other medicinal products and other forms of interaction

Prucalopride has a low pharmacokinetic interaction potential. It is extensively excreted unchanged in urine (approximately 60% of the dose) and *in vitro* metabolism is very slow.

Prucalopride did not inhibit specific CYP450 activities in *in vitro* studies in human liver microsomes at therapeutically relevant concentrations.

Although prucalopride may be a weak substrate for P-glycoprotein (P-gp), it is not an inhibitor of P-gp at clinically relevant concentrations.

Effects of prucalopride on pharmacokinetics of other medicinal products

A 30% increase in plasma concentrations of erythromycin was found during prucalopride co-administration. The mechanism for this interaction is not clear.

Prucalopride had no clinically relevant effects on the pharmacokinetics of warfarin, digoxin, alcohol, paroxetine or oral contraceptives.

Effects of other medicinal products on pharmacokinetics of prucalopride

Ketoconazole (200 mg twice daily), a potent inhibitor of CYP3A4 and of P-gp, increased the systemic exposure to prucalopride by approximately 40%. This effect is too small to be clinically relevant.

3

Interactions of similar magnitude may be expected with other potent inhibitors of P-gp such as verapamil, cyclosporine A and quinidine.

Therapeutic doses of probenecid, cimetidine, erythromycin and paroxetine did not affect the pharmacokinetics of prucalopride.

4.6 Fertility, pregnancy and lactation

Women of childbearing potential

Women of childbearing potential have to use effective contraception during treatment with prucalopride

Pregnancy

There is a limited amount of data from the use of prucalopride in pregnant women. Cases of spontaneous abortion have been observed during clinical studies, although, in the presence of other risk factors, the relationship to prucalopride is unknown. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (including pregnancy, embryonal/ foetal development, parturition or postnatal development) (see section 5.3). PRUCAWIN is not recommended during pregnancy and in women of childbearing potential not using contraception.

Breast-feeding

A human study has shown that prucalopride is excreted in breast milk. At therapeutic doses of PRUCAWIN

, no effects on breast-fed newborns/infants are anticipated. In the absence of human data in women who actively breast-fed while taking PRUCAWIN, a decision should be made whether to discontinue breast-feeding or to discontinue PRUCAWIN therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.

Fertility

Animal studies indicate that there is no effect on male or female fertility.

4.7 Effects on ability to drive and use machines

PRUCAWIN may have a minor influence on the ability to drive and use machines, since dizziness and fatigue have been observed in clinical studies, particularly during the first day of treatment (see section 4.8).

4.8 Undesirable effects

Summary of the safety profile

In an integrated analysis of 17 double-blind placebo-controlled studies, PRUCAWIN was given orally to approximately 3,300 patients with chronic constipation. Of these, over 1,500 patients received PRUCAWIN at the recommended dose of 2 mg per day, while approximately 1,360 patients were treated

with 4 mg prucalopride daily. The most frequently reported adverse reactions associated with PRUCAWIN 2 mg therapy are headache (17.8%) and gastrointestinal symptoms (abdominal pain (13.7%), nausea

(13.7%) and diarrhoea (12.0%)). The adverse reactions occur predominantly at the start of therapy and usually disappear within a few days with continued treatment. Other adverse reactions have been reported occasionally. The majority of adverse events were mild to moderate in intensity.

Tabulated list of adverse reactions

The following adverse reactions were reported in controlled clinical studies at the recommended dose of 2 mg with frequencies corresponding to very common ($\geq 1/10$), common ($\geq 1/100$ to $< 1/10$), uncommon ($\geq 1/1,000$ to $< 1/100$), rare ($\geq 1/10,000$ to $< 1/1,000$), very rare ($< 1/10,000$) and not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. Frequencies are calculated based on the integrated analysis of 17 double-blind placebo-controlled clinical studies.

4

Table 1: Adverse Drug Reactions (ADRs) Associated with PRUCAWIN		
System/Organ Class	Incidence Category	Adverse Drug Reaction
Metabolism and nutrition disorders	Common	Decreased appetite
Nervous system disorders	Very common	Headache
	Common	Dizziness
	Uncommon	Tremors, migraine
Cardiac disorders	Uncommon	Palpitations
Ear and labyrinth disorders	Uncommon	Vertigo
Gastrointestinal disorders	Very common	Nausea, diarrhoea, abdominal pain
	Common	Vomiting, dyspepsia, flatulence, gastrointestinal sounds abnormal
	Uncommon	Rectal haemorrhage
Renal and urinary disorders	Uncommon	Pollakiuria

General disorders and administration site conditions	Common	Fatigue
	Uncommon	Pyrexia, malaise

Description of selected adverse reactions

After the first day of treatment, the most common adverse reactions were reported in similar frequencies (incidence no more than 1% different between prucalopride and placebo) during PRUCAWIN therapy as during placebo, with the exception of nausea and diarrhea that still occurred more frequently during PRUCAWIN therapy, but less pronounced (differences in incidence between PRUCAWIN and placebo of 1.3% and 3.4%, respectively).

Palpitations were reported in 0.7% of the placebo patients, 0.9% of the 1 mg prucalopride patients, 0.9% of the 2 mg prucalopride patients and 1.9% of the 4 mg prucalopride patients. The majority of patients continued using prucalopride. As with any new symptom, patients should discuss the new onset of palpitations with their physician.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in [Appendix V](#)

4.9 Overdose

In a study in healthy volunteers, treatment with prucalopride was well tolerated when given in an up-titrating scheme up to 20 mg once daily (10 times the recommended therapeutic dose). An overdose may result in symptoms resulting from an exaggeration of prucalopride's known pharmacodynamics effects and include headache, nausea and diarrhea. Specific treatment is not available for PRUCAWIN overdose. Should an overdose occur, the patient should be treated symptomatically and supportive measures instituted, as required. Extensive fluid loss by diarrhoea or vomiting may require correction of electrolyte disturbances.

5

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamics properties

Pharmacotherapeutic group: Other drugs for constipation, ATC code: A06AX05.

Mechanism of action

Prucalopride is a dihydrobenzofurancarboxamide with gastrointestinal prokinetic activities. Prucalopride is a selective, high affinity serotonin (5-HT₄) receptor agonist, which is likely to explain its prokinetic effects. *In vitro*, only at concentrations exceeding its 5-HT₄ receptor affinity by at least 150-fold, affinity for other receptors was detected. In rats, prucalopride *in vivo*, at doses above 5 mg/kg (at and above 30-70 times the clinical exposure), induced hyperprolactinaemia caused by an antagonistic action at the D₂ receptor.

In dogs, prucalopride alters colonic motility patterns via serotonin 5-HT₄ receptor stimulation: it stimulates proximal colonic motility, enhances gastroduodenal motility and accelerates delayed gastric emptying. Furthermore, giant migrating contractions are induced by

prucalopride. These are equivalent to the colonic mass movements in humans, and provide the main propulsive force to defaecation. In dogs, the effects observed in the gastrointestinal tract are sensitive to blockade with selective 5-HT₄ receptor antagonists illustrating that the observed effects are exerted via selective action on 5-HT₄ receptors.

These pharmacodynamic effects of prucalopride have been confirmed in human subjects with chronic constipation using manometry in an open-label, randomized, crossover, reader-blinded study investigating the effect of prucalopride 2 mg and an osmotic laxative on colon motility as determined by the number of colonic high-amplitude propagating contractions (HAPCs, also known as giant migrating contractions). Compared with a constipation treatment working through osmotic action, prokinetic stimulation with prucalopride increased colonic motility as measured by the number of HAPCs during the first 12 hours after intake of the investigational product. The clinical significance or benefit of this mechanism of action when compared with other laxatives has not been investigated.

Clinical efficacy and safety

Adult population

The efficacy of PRUCAWIN was established in three multicenter, randomized, double-blind, 12-week placebo-controlled studies in subjects with chronic constipation (n=1,279 on PRUCAWIN, 1,124 females, 155 males). The PRUCAWIN doses studied in each of these three studies included 2 mg and 4 mg once daily. The primary efficacy endpoint was the proportion (%) of subjects that reached normalization of bowel movements defined as an average of three or more spontaneous, complete bowel movements (SCBM) per week over the 12-week treatment period.

The proportion of female patients in whom laxatives fail to provide adequate relief treated with the recommended dose of 2 mg PRUCAWIN (n=458) that reached an average of ≥ 3 SCBM per week was 31.0% (week 4) and 24.7% (week 12), versus 8.6% (week 4) and 9.2% (week 12) on placebo. A clinically meaningful improvement of ≥ 1 SCBM per week, the most important secondary efficacy endpoint, was achieved in 51.0% (week 4) and 44.2% (week 12) treated with 2 mg PRUCAWIN versus 21.7% (week 4) and 22.6% (week 12) of placebo patients.

The effect of PRUCAWIN on spontaneous bowel movements (SBM) also proved to be statistically superior to placebo for the portion of patients that had an increase of ≥ 1 SBM/week over the 12-week treatment period. At week 12, 68.3% of patients treated with 2 mg prucalopride had an average increase of ≥ 1 SBM/week versus 37.0% of placebo patients ($p < 0.001$ vs placebo).

In all three studies, treatment with PRUCAWIN also resulted in significant improvements in a validated and disease specific set of symptom measures (PAC-SYM), including abdominal (bloating, discomfort, pain and cramps), stool (incomplete bowel movements, false alarm, straining, too hard, too small) and

6

rectal symptoms (painful bowel movements, burning, bleeding/tearing), determined at week 4 and week 12. At week 4, the proportion of patients with an improvement of ≥ 1 versus baseline in the PAC-SYM abdominal, stool, and rectal symptom subscales was 41.3%, 41.6%, and 31.3% respectively in patients treated with prucalopride 2 mg compared with 26.9%, 24.4% and 22.9% in patients on placebo. Similar results were observed at Week 12: 43.4%, 42.9%, and 31.7% respectively in 2 mg PRUCAWIN patients versus 26.9%, 27.2%, and 23.4% in placebo patients ($p < 0.001$ vs placebo).

A significant benefit on a number of Quality of Life measures, such as degree of satisfaction with treatment and with bowel habits, physical and psychosocial discomfort and worries and concerns, was also observed at both the 4 and 12-week assessment time points. At Week 4, the proportion of patients with an improvement of ≥ 1 versus baseline in the Patient Assessment of Constipation-Quality of Life satisfaction subscale (PAC-QOL) was 47.7% in patients treated with PRUCAWIN 2 mg compared with 20.2% in patients on placebo. Similar results were observed at Week 12: 46.9% in 2 mg PRUCAWIN patients versus 19.0% in placebo patients ($p < 0.001$ vs placebo).

In addition, the efficacy, safety and tolerability of PRUCAWIN in male patients with chronic constipation were evaluated in a 12-week, multi-center, randomized, double-blind, placebo-controlled study (N=370). The primary endpoint of the study was met: a statistically significantly higher percentage of subjects in the PRUCAWIN group (37.9%) had an average of ≥ 3 SCBMs/week compared with subjects in the placebo treatment group (17.7%) ($p < 0.0001$) over the 12-week double-blind treatment period. The safety profile of PRUCAWIN was consistent with that seen in female patients.

Long-term study

The efficacy and safety of PRUCAWIN in patients (aged ≥ 18 or older) with chronic constipation, were evaluated in a 24 week multicentre, randomized, double-blind, placebo controlled study (N=361). The proportion of patients with an average weekly frequency of ≥ 3 Spontaneous Complete Bowel Movements (SCBMs) per week (i.e., responders) over the 24-week double-blind treatment phase was not statistically different ($p = 0.367$) between the PRUCAWIN (25.1%) and placebo (20.7%) treatment groups. The difference between treatment groups in the average weekly frequency of ≥ 3 SCBMs per week was not statistically significant over Weeks 1-12 which is inconsistent with the 5 other multicentre, randomized, double-blind, 12-week placebo controlled studies demonstrating efficacy at this time point in adult patients. The study is therefore considered to be inconclusive with respect to efficacy. However, the totality of the data including the other double-blind placebo controlled 12 week studies support the efficacy of PRUCAWIN. The safety profile of prucalopride in this 24-week study was consistent with that seen in the previous 12 week studies.

PRUCAWIN has been shown not to cause rebound phenomena, nor to induce dependency.

TQT study

A thorough QT study was performed to evaluate the effects of PRUCAWIN on the QT interval at therapeutic (2 mg) and serotherapeutic doses (10 mg) and compared with the effects of placebo and a positive control. This study did not show significant differences between PRUCAWIN and placebo at either dose, based on mean QT measurements and outlier analysis. This confirmed the results of two placebo controlled QT studies. In double-blind clinical studies, the incidence of QT-related adverse events and ventricular arrhythmias was low and comparable to placebo.

Paediatric population

The efficacy and safety of PRUCAWIN in pediatric patients (aged 6 months to 18 years) with functional constipation, were evaluated in an 8-week double-blind, placebo-controlled trial (N=213), followed by a 16 week open-label comparator-controlled (Polyethylene glycol 4000) study of up to 24 weeks (N=197). The starting dose administered was 0.04 mg/kg/day titrated between 0.02 and

0.06 mg/kg/day (to a maximum of 2 mg daily) for children weighing ≤ 50 kg given as an oral solution of PRUCAWIN or matching placebo. Children weighing >50 kg received 2 mg/day PRUCAWIN tablets or matching placebo.

Response to the treatment was defined as having an average of ≥ 3 spontaneous bowel movements (SBMs) per week and an average number of faecal incontinence episodes of ≤ 1 per 2 weeks. The

7

results of the study showed no difference in efficacy between PRUCAWIN and placebo with response rates of 17% and 17.8% respectively ($P=0.9002$). PRUCAWIN was generally well tolerated. The incidence of subjects with at least 1 treatment-emergent adverse event (TEAE) was similar between the PRUCAWIN treatment group (69.8%) and the placebo treatment group (60.7%). Overall, the safety profile of PRUCAWIN in children was the same as in adults.

5.2 Pharmacokinetic properties

Absorption

Prucalopride is rapidly absorbed; after a single oral dose of 2 mg in healthy subjects, $C_{\max}$ was attained in 2-3 hours. The absolute oral bioavailability is $>90\%$. Concomitant intake of food does not influence the oral bioavailability of prucalopride.

Distribution

Prucalopride is extensively distributed, and has a steady-state volume of distribution (V_{dss}) of 567 litres. The plasma protein binding of prucalopride is about 30%.

Biotransformation

Metabolism is not the major route of elimination of prucalopride. *In vitro*, human liver metabolism is very slow and only minor amounts of metabolites are found. In an oral dose study with radiolabelled prucalopride in man, small amounts of seven metabolites were recovered in urine and faeces. The quantitatively most important metabolite in excreta, R107504, accounted for 3.2% and 3.1% of the dose in urine and faeces, respectively. Other metabolites identified and quantified in urine and faeces were R084536 (formed by N-dealkylation) accounting for 3% of the dose and products of hydroxylation (3% of the dose) and N-oxidation (2% of the dose). Unchanged active substance made up about 92-94% of the total radioactivity in plasma. R107504, R084536 and R104065 (formed by O-demethylation) were identified as minor plasma metabolites.

Elimination

A large fraction of the active substance is excreted unchanged (60-65% of the administered dose in urine and about 5% in faeces). Renal excretion of unchanged prucalopride involves both passive filtration and active secretion. The plasma clearance of prucalopride averages 317 ml/min. Its terminal half-life is about one day. Steady-state is reached within three to four days. On once daily treatment with 2 mg prucalopride, steady-state plasma concentrations fluctuate between trough and peak values of 2.5 and 7 ng/ml, respectively. The accumulation ratio after once daily dosing ranged from 1.9 to 2.3. The pharmacokinetics of prucalopride is dose-proportional within and beyond the therapeutic range (tested up to 20 mg). Prucalopride o.d. displays time-independent kinetics during prolonged treatment.

Special populations

Population pharmacokinetics

A population pharmacokinetic analysis showed that the apparent total clearance of prucalopride was correlated with creatinine clearance, but that age, body weight, sex or race had no influence.

Older people

After once daily dosing of 1 mg, peak plasma concentrations and AUC of prucalopride in older people were 26% to 28% higher than in young adults. This effect can be attributed to a diminished renal function in older people.

Renal impairment

Compared to subjects with normal renal function, plasma concentrations of prucalopride after a single 2 mg dose were on average 25% and 51% higher in subjects with mild (Cl_{CR} 50-79 ml/min) and moderate (Cl_{CR} 25-49 ml/min) renal impairment, respectively. In subjects with severe renal impairment ($Cl_{CR} \leq 24$ ml/min), plasma concentrations were 2.3 times the levels in healthy subjects (see section 4.2 and 4.4).

8

Hepatic impairment

Non-renal elimination contributes to about 35% of total elimination. In a small pharmacokinetic study, the C_{max} and AUC of prucalopride were, on average, 10-20% higher in patients with moderate to severe hepatic impairment compared with healthy subjects (see sections 4.2 and 4.4).

5.3 Preclinical safety data

Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, and toxicity to reproduction and development. An extended series of safety pharmacology studies with special emphasis on cardiovascular parameters showed no relevant changes in haemodynamic and ECG derived parameters (QTc) with the exception of a modest increase in heart rate and blood pressure observed in anaesthetised pigs after intravenous administration, and an increase in blood pressure in conscious dogs after bolus intravenous administration, which was not observed either in anaesthetised dogs or after oral administration in dogs reaching similar plasma levels. A subcutaneous neonatal/juvenile toxicity study performed in rats 7-55 days of age resulted in a NOAEL of 10 mg/kg/day. The AUC_{0-24h} exposure ratios at the NOAEL versus human children (dosed at approximately 0.04 mg/kg daily) ranged between 21 and 71 providing adequate safety margins for the clinical dose.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Lactose monohydrate
microcrystalline cellulose (PH 112)
Colloidal silicon dioxide

Magnesium stearate
Crospovidone XL 10
Polacrilin Potassium (Kyron T-314)
Purified Talcum
DRCOAT FCU (Color code :C/011/025)
Isopropyl alcohol (IPA) @,Methylene Dichloride (MDC) @

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

36 years.

6.4 Special precautions for storage

Storage condition Below 30°C. Store protected from moisture.

6.5 Nature and contents of container

1 X 10 Tablet Alu Alu Blister

6.6 Special precautions for disposal

No special requirements.

7. MARKETING AUTHORISATION HOLDER

(Company) Name: WIN-PHARMA LTD

Address: P.O. BOX 50185, 00200 – NAIROBI, KENYA

Telephone: +254723485818

E-Mail: marketing@winpharma.co.ke

sales@winpharma.co.ke

admin@winpharma.co.ke

info@winpharma.co.ke

Manufactured By:

4Care life Science (P) Limited

SurveyNo.23/3P&24,

Opp. Jeans Factory, Daduram Vistar, Village-Bagdol, Tal- Kathlal, Dist-
Kheda - 387630, Gujarat, India.

E-Mail: tushar@4care.in

8. MARKETING AUTHORISATION NUMBER(S):

N/A

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION:

N/A

10. DATE OF REVISION OF THE TEXT:

10/07/2026